Cerenome Reported $1.55 Million in Q3 Gross Billings
Houston-based Cerenome is expanding its diagnostic test coverage ahead of a key January Medicare pricing decision.
Live Poll
Do you believe expanding diagnostic testing coverage improves patient access to necessary care?